START WITH THE ANSWER
Did aspirin extend healthy independent life in older adults without prior cardiovascular disease?
Not in the main ASPREE trial period. It did not prolong disability-free survival and increased major hemorrhage. This is evidence about starting prevention in the studied setting, not an instruction to stop medicine prescribed for another reason.
The question was primary prevention
ASPREE enrolled 19,114 community-dwelling older adults without cardiovascular disease, dementia or substantial physical disability at entry. They were randomized to aspirin or placebo. The primary outcome combined death, dementia and persistent physical disability, aiming to test whether the intervention preserved healthy independent life. This is different from asking how to prevent another event in someone who has already had a heart attack or stroke. The NIH explanation emphasizes that the study addressed otherwise healthy older people without previous cardiovascular events. Keeping that distinction is essential because a treatment can have a different benefit-harm balance when baseline risk and the reason for use differ.
The desired benefit did not appear, while bleeding increased
At a median 4.7 years, the composite event rate was 21.5 versus 21.2 per 1,000 person-years for aspirin and placebo, with a hazard ratio of 1.01. Major hemorrhage occurred in 3.8% versus 2.8%, respectively. The main result therefore did not support prolonging disability-free survival with this intervention in the enrolled population. The absolute bleeding difference was about one percentage point over the trial period; this is not one extra event per hundred people every year. The publication also described declining adherence, so the result belongs to how the trial was actually conducted. A familiar, inexpensive intervention still needed this comparison to reveal its overall value.
A mechanism can point toward benefit and harm
The appeal of preventive treatment often starts with a biological rationale: reducing one process might prevent one kind of event. But a whole person has several outcomes at stake, and the intervention may affect more than the desired pathway. In a population with relatively low risk of the target event, a modest benefit can be offset by a different harm. That is why healthy-longevity claims should include the actual population, comparator and competing outcomes. Consider a fictional supplement or drug marketed with only a favorable laboratory marker. The ASPREE lesson is not that all preventive treatments fail; it is that apparently sensible prevention can disappoint when tested on outcomes people care about. Familiarity, low price and a long history of use do not replace an appropriate trial for a new purpose. An existing prescription also has its own indication, which should be reviewed with the prescribing clinician rather than changed from a website lesson.
Read benefit and harm on the same timeline
For this trial, place the disability-free-survival result and major-bleeding result side by side. Keep percentages over follow-up separate from rates per person-year. Then identify the population to which the comparison belongs before applying its headline to a different prevention situation.
What to take away
- Primary prevention differs from preventing a recurrence after disease.
- Benefits and harms need the same population and time horizon.
CHECK YOUR UNDERSTANDING
Does ASPREE instruct someone with an existing cardiovascular prescription to stop aspirin?
Think it through, then reveal the explanation
No. It tested a different prevention context; an existing indication and treatment decision require an individual clinical review.
A learning question, not a health assessment. No answers are collected or saved.
Original material & reading scope
Trial McNeil et al.: Effect of Aspirin on Disability-free Survival in the Healthy Elderly
Read original indexed NEJM abstract and opened PMC article; subsequent PMC requests challenged. Numbers follow the paper, not rounded press summaries.
Checked 2026-09-21 · 2018
Open original source Lessons using this sourceOfficial guidance NIH: Aspirin did not prolong healthy independent living in ASPREE
Read indexed official funder release; direct page returned an error. Used for prevention context, not its differently rounded bleeding percentage.
Checked 2026-09-21 · 2018
Open original source Lessons using this source